Enhertu Combo Eliminates Tumors in Mice

Regeneron researchers report that pairing Enhertu with an experimental bispecific antibody cleared tumors in animal studies.

Updated on Nov. 21, 2026 in Cancer

Unlabeled glass vials of pale amber liquid in a steel rack on a clean laboratory bench, representing cancer immunotherapy research.
Regeneron researchers reported that pairing Enhertu with an experimental bispecific antibody cleared tumors in mice, and treated mice rejected later cancer cell injections. AI Illustration. Upload story photo >

Researchers at Regeneron Pharmaceuticals reported that combining Enhertu, sold as trastuzumab deruxtecan, with an experimental bispecific antibody eliminated tumors in mice. Mice that cleared their tumors also rejected a later injection of the same cancer cells without further treatment.

Why it matters

The work aims to strengthen cancer treatment by helping the immune system join the attack against tumors. Some combinations may reduce treatment burden if the results are confirmed in patients, though the findings so far come from animal studies.

The initial breast cancer tests included nine mice receiving both treatments, all of which had their tumors eliminated. Tumor-free mice for at least four weeks rejected re-injected cancer cells, while removing CD8 T cells eliminated the combination's benefit.

The players

Regeneron Pharmaceuticals

A New York-based biopharmaceutical company that develops and commercializes medicines for serious diseases, including cancer, and that funded the study and employs all of its authors.

The details

The experimental antibody binds a protein on tumor cells and CD28, an activation protein on T cells, while Enhertu increased and activated dendritic cells that present tumor material to T cells. The combinations also increased active T cells and the diversity of T cell receptors, according to the study.

Health Landscape

The work builds on the approved antibody-drug conjugate Enhertu by testing whether adding an immune-activating antibody can extend its effect beyond what the drug achieves alone. It reflects a broader push in cancer research to combine targeted therapies with treatments that recruit the body's own T cells.

The findings are at the animal-study stage, so they do not change current treatment options for cancer patients. Any eventual clinical use would depend on human trials confirming safety and benefit before the combination could reach patients.

The takeaway

Animal results like these are an early step, and readers should watch for human clinical trial data before drawing conclusions about treatment benefits. Progress in cancer care typically depends on that confirmation.

Further reading

For related coverage, explore more Cancer research and treatment news.

Source note: This article includes information reported by ScienceAlert.